InspireMD (NYSE:NSPR) vs. Minerva Surgical (NASDAQ:UTRS) Critical Survey

Minerva Surgical (NASDAQ:UTRS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Analyst Recommendations

This is a summary of current recommendations for Minerva Surgical and InspireMD, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Surgical	0	0	0	0	0.00
InspireMD	0	0	1	0	3.00

InspireMD has a consensus price target of $4.00, indicating a potential upside of 86.05%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Minerva Surgical.

Earnings & Valuation

This table compares Minerva Surgical and InspireMD”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	0.00
InspireMD	$7.78 million	11.71	-$19.92 million	($0.84)	-2.56

InspireMD has lower revenue, but higher earnings than Minerva Surgical. InspireMD is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Minerva Surgical has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

44.8% of InspireMD shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by insiders. Comparatively, 29.7% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Minerva Surgical and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Surgical	N/A	N/A	N/A
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats Minerva Surgical on 8 of the 14 factors compared between the two stocks.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.